News | November 07, 2024
Mitsui Chemicals invests in clinical kidney disease drug developer Rege Nephro
The company uses iPS cells to develop treatments for diseases relating to the kidney
The company uses iPS cells to develop treatments for diseases relating to the kidney
Results from the open-label extension study of PHOTON demonstrate patients with diabetic macular edema (DME) randomized to Eylea 8 mg maintained visual and anatomic improvements at the end of three years
US$ 800 million senior secured notes, the largest high yield debut USD bond issuance from India in the last 10 years
AMR poses a critical threat to global public health undermining decades of progress made in the field of modern medicine
The Notes shall not be offered or sold in India
ACOIN has recognized Dr. Budhrani's exceptional work in promoting community and clinical ophthalmology
India's bio economy has experienced remarkable growth, skyrocketing from US $10 billion in 2014 to over $130 billion in 2024, with projections to reach $300 billion by 2030
The companies will combine Nanoform’s Biologics platform with the Celanese VitalDose Drug Delivery platform to further optimize controlled release of biologics
This Fast Track Designation will enable FDA to review MM-II in an expedited manner, is an important milestone in the development of MM-II
The study highlighted substantial improvements in key clinical parameters among RA patients who underwent AWS intervention
Subscribe To Our Newsletter & Stay Updated
